Market and product assessment of probiotic/prebioticcontaining functional foods and supplements manufactured in South Africa by Brink, M et al.
liD 
ORIGINAL ARTICLES 
Market and product assessment of probiotic/prebiotic-
containing functional foods and supplements manufactured 
in South Africa 
M Brink, M Senekal, L M T Dicks 
Objectives. Probiotic and prebiotic products manufactured in 
South Africa were identified and health and content claims 
stated on the labels were evaluated according to available 
scientific evidence, the proposed South African regulations 
in the Foodstuffs, Cosmetics and Disinfectants Act (Act No. 
54 of 1972, www.doh.gov.za), and microbial assessment. 
Results. The range of products identified included probiotic-
and/or prebiotic-containing supplements (capsules), food 
items fortified with probiotics and/ or prebiotics, and 
fermented food containing probiotics, e.g. dairy products. 
Most of the health-related claims on the labels of the 
identified products do not comply with proposed South 
African regulations. However, results also indicate that the 
proposed South African regulations should be reconsidered 
to include an additional 5 claims, for which scientifically 
sound evidence is available. The claims regarding probiotic 
strains, viable cell numbers, prebiotic type and concentration 
stated on the labels of the products are mostly in line with 
Consumers are becoming more aware of functional foods and 
supplements and the potential role of these products in a 
balanced diet and in ensuring good health.1 Functional foods 
are defined as foods that contain physiologically active 
components, which provide health benefits beyond basic 
nutrition' by affecting one or more functions in the body in a 
targeted way.' 'The functional component could include an 
essential macronutrient with specific physiological effects such 
as an essential micronutrient'', 'components that have some 
nutritive value but are not classified as "essential", such as 
oligosaccharides, or food components with no nutritive value, 
such as live microorganisms or plant chemicals' .3 'A dietary 
supplement is defined as a product intended for ingestion as a 
supplement to the diet'.' Supplements may contain one or 
more of the following ingredients: vitamins, minerals, herbs, 
botanicals, or other plant-derived substances; amino acids, 
enzymes, concentrates and extracts. Dietary supplements can 
be manufactured as pills, tablets, capsules, gelcaps, liquids and 
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the proposed South African regulations. The actual viable 
cell content of 3 out of 5 probiotic supplements readily 
available on the South African market did not comply with 
the content claim stated on the label. However, this problem 
did not seem to affect the inhibitory activity of the pro biotic 
strains against indicator strains isolated from faeces of 
patients diagnosed with AIDS. To validate this finding in 
vivo assessments should be implemented before considering 
the need to include a wider range of prescribed viable cell 
numbers in the proposed South African regulations. 
Conclusions. The proposed South African regulations 
regarding probiotic- and prebiotic-containing products 
should be revised based on the results of this research, and 
the manufacturers of these products should be held 
responsible for providing the consumer with scientifically 
sound and legally correct information. 
S Afr Med T 2005; 95: 114-119. 
powders.' 
In many countries the functional food market seems to be 
dominated by gut health products, in particular probiotic- and 
prebiotic-containing products.' Fuller' defines a probiotic as 'a 
live microbial food supplement that beneficially affects the host 
animal by improving its intestinal microbial balance'. 
Probiotics are available in the form of various pharmaceutical 
preparations, e.g. powders, liquid suspensions and tablets, or 
are incorporated in, for example, fermented food products to 
produce functional foods.'·' 
The latest trend in the functional food market is to combine 
probiotics with prebiotics to enhance the effect of probiotics.5 
Prebiotics are defined as 'non-digestible food ingredients that 
beneficially affect the host by selectively stimulating the 
growth and/ or activity of pro biotic bacteria in the colon'. 8 
However, p.rebiotics also have health benefits that are not 
related to the simultaneous intake of probiotics. Inulin and 
fructo-oligosaccharides are among the most common prebiotics 
included in breakfast cereals and nutritional drinks or used in 
combination with probiotics in nutritional supplements.' 
Because of the presence of potentially pathogenic species 
such as Enterococcus faecium and E. faecalis in probiotic 
products,uo the production and marketing of functional foods 
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should be strictly controlled and carefully monitored." 
Information on the label of the product, especially regarding 
the composition and iclentity of the probiotic strains included, 
needs to be accurate to guarantee safety and functionality. 12 
Recent studies conducted on probiotic supplements and dairy 
products in Europe and South Africa revealed possible 
irregularities in this regard. In most cases the identity and 
number of viable strains recovered did not correspond with the 
information on the label. 12-14 
One solution in addressing the problems mentioned with 
product content involves relevant and effective legislation. 
However, despite the large market segment occupied by 
probiotic foods and supplements in Europe, no specific 
regulations regarding the labelling of these products exist in 
that region.15 On the other hand, although this particular 
market has not yet been that well developed in the USA, the 
United States Food and Drug Administration (FDA) strictly 
regulates the labelling and marketing of conventional foods 
containing probiotic bacteria. In South Africa permissible 
statements regarding the health benefits of probiotic and 
prebiotic claims are included in the proposed regulations 
governing labelling and advertising in the Foodstuffs, 
Cosmetics and Disinfectants Act, 1972 (Act No. 54 of 1972 
(referred to as 'proposed South African regulations' from here 
onwards), www.doh.gov.za). However, despite the fact that 
these regulations are being finalised, limited information is 
available regarding the probiotic- and prebiotic-containing 
product market .in South Africa. 
In view of the above, the aims of this study were to complete 
a market and product assessment of probiotic- and prebiotic-
containing products manufactured in South Africa. This 
involved identifying the range of products available on the 
South African market and evaluating claims made on the 
labels. 
Materials and methods 
Identification of probiotic and prebiotic products on 
the South African market 
For the purposes of this study 'probiotic- and prebiotic-
containing products manufactured in South Africa' are defined 
as all products manufactured in South Africa that contain 
probiotics and/or prebiotics. For the identification of such 
products available on the South African market during the 
period 1 February - 1 September 2003, the following 
information sources were scrutinised or visited: general 
grocery outlets, health food stores, websites, published 
information including scientific literature, advertisements and 
pamphlets. Every identified product was listed and the 
following information was recorded: type of product (tablet, 
syrup or powdered form), specific target group (if applicable), 
probiotic strains (strain, number of viable cells (colony forming 
units (cfu)/g) and prebiotic (type and concentration). 
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Evaluation of claims on probiotic- and prebiotic-
containing products manufactured in South Africa 
For the purposes of this study 'claims' are defined as: (i) 
health-related claims, e.g. 'treatment and prevention of 
diarrhoea'; and (ii) probiotic and prebiotic content-related 
claims, i.e. strain and viable cell numbers of probiotics and 
concentration of prebiotics included. 
Evaluation of health-related claims based on proposed South 
African regulations 
The health-related claims regarding probiotics and prebiotics 
on each identified product were listed and similar claims were 
grouped together. To determine whether it complied with the 
regulations or not, the wording/content of each of the claims 
was subsequently compared with the prescribed wording/ 
content claim as proposed by the South African regulations. 
Evaluation of health claims based on scientific soundness 
The scientific soundness of each of the identified claims was 
assessed by searching the scientific literature for any published 
study providing data in support of the claim. In this process it 
was assumed that the publication of a paper in a scientific 
journal is not necessarily final proof of the scientific soundness 
of such a claim. To address this issue, the quality of each 
identified paper was assessed based on the study design 
applied. According to Farnworth/' it is generally accepted that 
health claims concerning specific nutrients/foods/functional 
components need to be assessed using a randomised controlled 
trial (RCn. The following criteria of RCTs in humans' were 
therefore used to assess the quality of the identified papers: 
(i) the measurements used must be objective - subjective 
claims, referred to as anecdotal evidence, which include 
individual testimonials or opinions, are not acceptable objec-
tive measurements; (ii) the experimental population must be 
appropriate, i.e. human, and the subjects used must be 
in line with those for whom conclusions were drawn and 
recommendations formulated - for example, it is not 
acceptable to use adult subjects and formulate health claims 
for children; (iii) the study must includea control group; (iv) 
the study must include an experimental group; (v) subjects 
must be randomly assigned to an experimental and control 
group; (vi) control subjects must receive a placebo; (vii) the 
study must be at least single-blinded, but preferably double-
blinded; and (viii) the journal in which the study was 
published must be peer reviewed. 
Although sample size is a very important factor to consider 
in a study design, it was not possible to specify a minimum 
sample size for a scientifically sound study for the assessment IJII 
of probiotic- and prebiotic-related health claims. A criterion in 
this regard was therefore not formulated. 
A study was classified as scientifically sound if at least 7 out 
of 8 of the mentioned criteria were met. If any 2 or more of the 
criteria were not met, the study was classified as lacking in 
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scientific soundness, although not necessarily completely 
worthless. Although in vitro studies supply important 
evidence regarding microbial activity and potential health 
benefits, the final proof lies in the execution of well-planned 
RCTs. In vitro studies were therefore not accepted as a 
scientific basis for the formulation of a health claim. 
Evaluation of content claims regarding strains included, 
viable cell numbers and prebiotic type and concentration 
based on the proposed South African regulations 
The pro biotic strains and viable cell numbers, and prebiotic 
type and concentration were listed for each identified product 
and compared with the proposed South African regulations in 
this regard. 
Microbial assessment of viable cell numbers included in 5 
selected probiotic supplements 
Five probiotic supplements readily available in pharmacies 
were selected to determine the viability (growth and inhibitory 
activity) of the probiotic strains and to compare the actual 
viable cell numbers with the 'label' claim in this regard. 
The content of the capsule was resuspended in 10 ml sterile 
distilled water, serially diluted and plated out, in duplicate, 
onto a De Man Rogosa Sharpe (MRS) agar (Biolab, Diagnostics, 
Midrand, South Africa). Plates from each dilution were 
incubated aerobically and anaerobically at 37°C and colonies 
were counted after 24 hours. 
To assess the viability of the probiotics included in the 
products, probiotic strains isolated from each of the 5 products 
were screened for inhibitory activity against the following 10 
indicator strains isolated from the faeces of patients diagnosed 
with AIDS: Salmonella typhi, S. typhimurium, Salmonella Gr. B., 
Shigella flexneri 1, S. flexneri 3, S. sonnei, S. boydii, Shigella spp., 
Yersinia spp. and Vibrio parahaemolyticus. The probiotic strains 
were cultured in MRS broth (Biolab) for 18 hours at 37°C and 
10 pl was spotted on MRS agar (Biolab). The plates were 
incubated for 24 hours at 37°C and then lawned with active 
cells of the indicator strains (approximately 10' cfu/ml), 
embedded in soft agar (0.8%, m/v). The plates were incubated 
at 37°C for 24 hours and the colonies examined for the 
formation of zones, which indicates the level of inhibitory 
activity and therefore viability. The study was done in 
triplicate and the average determined. 
Results 
The identified range of probiotic- and prebiotic-containing 
products manufactured in South Africa includes 3 fortified 
infant foods, 7 yoghurt products selected from a variety of 
dairy products containing live cultures targeted at children and 
adults, and 16 probiotic supplements of which 3 are targeted at 
infants/ children and 13 at adults. A combination of probiotics 
and prebiotics was found in 6 supplements, of which only 1 is 
targeted at children, 2 energy drinks and 1 dairy product 
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targeted at children and adults. Sixteen food items naturally 
containing or fortified with prebiotics, including 2 supple-
ments, 2 breakfast cereals, 11 nutritional drinks and 1 muesli 
bar, were identified. Four of these are targeted at infants/ 
children, 4 at children and adults, and 8 at adults only. 
Comparison of the health claims stated on the label of 
probiotic- and prebiotic-containing products manufactured in 
South Africa with the proposed South African regulations is 
presented in Table I. Scientific publications that seem to 
support a particular claim are listed in the table. 
These data indicate that only 3 of the 26 claims on the 
identified products comply with the proposed South African 
regulations, but that sound scientific evidence seems to be 
available for all 3 of these claims. It is of importance to note 
that sound scientific evidence is also available for at least 5 
claims not included in the proposed South African regulations, 
including diarrhoea prevention in infants, diarrhoea prevention 
in adults, improvement of digestive health and stool quality 
and prevention of constipation, treatment of irritable bowel 
syndrome, and treatment of food allergies. Furthermore, no 
sound scientific evidence could be traced for 16 of the 26 claims 
that appeared on the identified products. 
Probiotic strain claims made on the labels of identified 
products all comply with the proposed South African 
regulations with the exception of 4 dairy products and 1 
supplement. The claims concerning the included viable cell 
numbers varied between 1 x108 cfu/g and 6 x10' cfu/g, which 
is in line with the proposed South African regulations. The 
prebiotic type claims made on the labels of the identified 
products include fructo-oligosaccharides, raftilose and chicory, 
which are all permissible according to the proposed South 
African regulations. The labels of 3 products did not specify 
the type of prebiotic but only claimed prebiotic fibre content, 
which is not in line with the proposed South African 
regulations. The prebiotic concentration claims varied between 
3 g and 15 g per 100 g, which is in line with the proposed 
South African regulations. 
Comparison of viable cell numbers stated on the labels of the 
supplements with the actual viable cell numbers is presented in 
Table II. Based on these results, the viable cell numbers in 
supplements 1 and 5 are in line with the viable cell numbers as 
stated on the labels. The viable cell numbers in supplement 2 
were 2 log-cycles lower, and in supplements 3 and 4, 1 log-
cycle lower than the claimed number. The actual viable cell 
numbers in supplement 4 do not comply with the proposed 
South African regulations. 
The results of the screening of the probiotic strains isolated 
from the 5 selected supplements against a panel of 10 indicator 
strains are presented in Table III. It is evident that all strains 
showed good inhibitory activity against the panel of indicator 
strains isolated from faeces of patients diagnosed with AIDS, as 




Table I. Claims stated on the labels of pro biotic- and/or pre biotic-containing products, publications supporting claims and 
compliance with the proposed South African regulations 
Claims 
Prevention of diarrhoea in infants 
Assists in prevention and treatment of 
nappy rash 
Assists in prevention and treatment 
of constipation 
Assists in protection of infants in 
hygienically compromised situations 
Decreases symptoms of lactose intolerance 
Treatment of colon disorders 
Replenishes intestinal flora of adults 
(after antibiotic treatment) 
Helps the body to alleviate diarrhoea 
naturally in adults 
Improves digestive health, improves 
stool quality, prevents constipation 
Helps the body to alleviate 
flatulence naturally 
Reverses the negative effects of 
antibiotics on the digestive tract 
Reverses the negative effects of 
alcohol on the digestive tract 
Reverses the negative effects of 
stress on the digestive tract 
Reverses the negative effects of 
poor diet on the digestive tract 
Inhibits intestinal and food 
poisoning pathogens including 
Escherichia coli, Streptococci and 
Salmonella and feeds friendly 
bacteria, balances intestinal pH 
Assists in promotion of healthy 
bowel flora for treatment of acidity, 
heartburn, indigestion and digestive upsets 
Very effective in treating irritable 
bowel syndrome I colitis I 
radiation-caused enterocolitis 
Very effective in treating Crohn's disease 
Very effective in preventing dyspepsia 
Restores and maintains the normal 
vaginal flora (mainly lactic acid bacteria) 
frequently destroyed by the administration 
of broad-spectrum antibiotics and the use 
of disinfectants, soaps and deodorants 
Treatment of food allergies 
Treatment of acne 
Boosts immune system 
Treatment during steroid therapy 
Treatment during chemotherapy 
Treatment during radiotherapy 
Discussion 
References complied with 718 criteria 
Kaila et al.,17 Saavedra et al,/8 Shornikova 
et al.,I' Guandalini et al.,20 Haschke et al./1 




Vesa et al.24 
None 
Sittonen et al./5 Orrhage et al.," Cremonini et al." 
Sittonen et al.," Orrhage et al.,26 Cremonini et al." 








Pelto et al.," Gionchetti et al.,30 Niedzielin et al.3l 
Pelto et al." 
None 
None 
Heyman et al.,'' Majamaa et al.,33 Isola uri et al." 
None 
Link-Amster et al.,35 Schiffrin et al.,36 Mattila-
Sandholm and Kauppila,1 Fisberg et al.,'' Haschke et al.'1 
None 
None 
Hendriksson et al.38 




























The probiotic- and prebiotic-containing product market is a 
fast-growing industry worldwide and the list of available 
products increases on a daily basis.39 In the USA, Europe and 
Japan the probiotic and prebiotic market seems to be 
dominated by dairy products, including yoghurt and 
fermented drinks.'"A1 Although not an exhaustive list, a large 




Table II. Comparison of the actual viable cell numbers with the claims on the labels of 5 pro biotic supplements manufactured 
in South Africa · 
Supplement 
Viable cell numbers stated on the 
label of the supplement (cfu/g) 







1 X 108 
1 X 108 
1 X 108 
1 X 108 
1 X 10' 
1 X 108/1.7 X 108 
2.8 X 106/3 X 106 
2 X 107 
4 X 10'/1.4 X 107 
1.5 X 107 
*Supplements 3 and 5 contained no bifidobacteria and cell counts were not determined from anaerobically incubated plates. 
variety of probiotic- and prebiotic-containing products 
manufactured in South Africa were identified in this study. 
The range of products on the South African market includes 
probiotic and prebiotic supplements (capsules) and fortified 
food items, fermented foods containing probiotics, e.g. dairy 
products, and probiotics used in combination with prebiotics in 
supplements and food fortification. Dairy products seem 
to be prominent in the market, although fortified cereals, 
especially baby cereals, and supplements also seem to be 
growing markets. 
It is important that the health claims stated on the labels of 
products supply the consumer with reliable information 
because such claims influence consumer behaviour and 
potentially affect public health." From this research it was 
evident that quite a number of claims stated on the labels of 
products cannot be substantiated by scientific evidence and are 
therefore misleading. Besides the fact that the consumer is 
being manipulated into buying a product under false 
pretences, it could potentially be dangerous if such products 
are used to treat a condition instead of the individual seeking 
medical help.'' Manufacturers and marketers of these products 
should therefore be held accountable for health-related claims 
on products via appropriate legislation. 
Unlike the European situation,40 South African legislators 
have formulated proposed regulations for labelling of 
probiotic- and/ or pre biotic-containing products in the 
Foodstuffs, Cosmetics and Disinfectants Act (Act No. 54 of 
1972, www.doh.gov.za). Only 3 of 26 claims complied with 
proposed South African regulations. Sound scientific evidence 
was found for 5 additional claims not included in these 
regulations. Because of incomplete information on labels, the 
consumer is misinformed. We propose a revision of the South 
African regulations to include the following 5 claims: diarrhoea 
prevention in infants, diarrhoea prevention in adults, 
improvement of digestive health and stool quality and 
prevention of constipation, treatment of irritable bowel 
syndrome, and treatment of food allergies. 
The probiotic and prebiotic content-related claims (strain, 
viable cell number, type of probiotic and prebiotic concen-
tration) on the labels were mostly in line with the proposed 
South African regulations. Probiotic cultures most commonly 
claimed on the labels of supplements and functional foods 
include Lactobacillus acidophilus, Bificobacterium bifidum and 
B.longum, which are the same species generally claimed to be 
included in European pro biotic supplementsY It is of concern 
that quite a number of products on the South African market 
only claim L. acidophilus and Bifidobacterium sp. (AB-culture) 
content or prebiotic fibre content without specifying probiotic 
species, viable cell numbers, prebiotic type and concentration. 
This situation indicates that the proposed South African 
Table III. Inhibitory activity of probiotic strains from 5 probiotic supplements manufactured in South Africa against a panel 
of indicator strains 
Supplement Supplement Supplement Supplement Supplement 
1 2 3 4 5 
Human pathogens Zone size (mm) 
Salmonella typhi 26-30 26-30 26-30 26-30 26-30 
Yersinia spp. 26-30 20-25 26-30 20-25 20-25 
Shigella flexneri 1 31-35 26-30 26-30 20-25 26-30 
Salmonella typhimurium 31-35 31-35 20-25 26-30 20-25 
Shigella flexneri 3 31-35 31-35 26-30 20-25 31-35 
Shigella sonnei 26-30 ~36 26-30 26-30 ~ 36 
Shigella boydii :2:36 ~36 26-30 31-35 ~36 
Salmonella Gr. B 26-30 31-35 31-35 26-30 31-35 
Shigella spp. :2:36 31-35 31-35 26-30 :2:36 
Vibrio parahaemolyticus 31-35 26-30 26-30 26-30 31-35 
February 2005, Vol. 95, No. 2 SAMJ 
ORIGINAL ARTICLES 
regulations are not being enforced and that it is not possible for 
the consumer to make a well-informed decision on the use of 
these products. It is vitally important to rectify this. 
Despite the fact that product label claims regarding viable 
cell numbers are in line with the proposed South African 
regulations, the same is not always true for the actual viable 
cell numbers in products, as seen for 3 of the 5 probiotic 
supplements tested. This phenomenon is not uncommon as 
Hamilton-Miller et a/.,13 Temmerman et alY and Elliot and 
Treversham14 also reported that the identity and number of 
viable strains recovered from probiotic supplements and dairy 
products in the UK, Europe and South Africa did not 
correspond with the information on the label in many 
instances. Hamilton-Miller and Shah" suggested that 
manufacturers should ensure careful manufacturing practices 
and proper storage of pro biotic-containing products to ensure 
cell survival. All the probiotic strains tested in this study 
showed good inhibitory activity against the indicator strains. 
These results might indicate that lower viable cell numbers 
could be effective and therefore in vivo assessments should be 
considered. 
Conclusions and recommendations 
A large variety of pro biotic- and prebiotic-containing products 
are available on the South African market. Marketers of these 
products are misleading consumers with a number of health 
claims that are not scientifically sound and that do not comply 
with legislation. The proposed South African regulations 
should be revised. The content-related claims on the labels 
mostly comply with the proposed South African regulations, 
although a number of products do not provide this 
information. It is also evident that the number of viable cells 
listed on labels is not always correct. The fact that this problem 
does not seem to affect the inhibitory activity of the pro biotic 
strains might point to the need to implement in vivo 
assessments. If this finding is validated, a wider range of 
prescribed viable cell numbers in the proposed South African 
regulations should be considered. We recommend that the 
proposed South African regulations be revised regularly to 
accommodate the results of ongoing scientific research in the 
field of probiotics and prebiotics. 
This study was funded by the Medical Research Council (MRC) 
and National Research Foundation (NRF). 
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